
Rossari Biotech Q4 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
No
Order
N/A
Capex
Yes
1 of 4 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Focus on growing HPPC segment (Home & Personal Care, Agro, Performance Chemicals) with healthy demand outlook for FY24.
- Animal Health and Nutrition (AHN) segment targeted for highest percentage growth; expected to double revenue in 2-3 years with new premix plant and new products.
- Exports growing rapidly with Rs.380 crore in FY23 vs Rs.264 crore last year, expected to continue increase.
- Consolidation through mergers of subsidiaries (Tristar and Unitop) by March 31, 2024, aiming for operational efficiencies and growth.
- Unitop and Tristar showed 20%+ YoY revenue growth in FY23 on a like-to-like basis, expected to maintain growth trajectory.
- Targeting absolute EBITDA growth of 20-30% in FY24 with controlled expenses and no major Capex.
- Volumes growth hard to quantify due to changing product mix but overall topline growth is the focus.
See what Rossari Biotech management said on margin guidance — free account, 30 seconds.
Fundraise plans
No- No specific mention of any new fundraising through debt or equity in the transcript.
- Interest cost for FY23 was Rs. 22.3 crore, partly due to consolidation accounting entries.
- For FY24, interest cost is expected to decrease as loan amounts reduce (Rs. 74 crore loan, Rs. 20 crore working capital currently).
- The company funded acquisition of an additional 16% stake in Tristar (Rs. 17 crore) through internal accruals, indicating use of internal funds rather than fresh fundraising.
- Cash and cash equivalents stand at Rs. 69.8 crore (FY23), with net cash flow from operations being healthy at Rs. 152.4 crore.
- Overall, the company emphasizes a strong balance sheet and internal accruals funding, with no direct indication of plans for new debt or equity issuance in the immediate future.
See what Rossari Biotech management said on order book — free account, 30 seconds.
Capex plans
Yes- No significant additional Capex planned for FY24 and the next two to three years; focus is on optimizing current assets and capacities.
- Small Capex ongoing in the Animal Health and Nutrition (AHN) segment to set up a premix plant for vitamins, mineral mixes, and enzymes.
- Capex also initiated in the agro space for scaling up silicone super wetters production.
- FY24 and FY25 estimated Capex around Rs. 40-50 crore.
- Overall strategy emphasizes growth mainly through business ramp-up and acquisitions rather than large capital investments.
- Merger of subsidiaries (Tristar and Unitop) planned by 31st March 2024 to consolidate operations and improve efficiencies.
Track Rossari Biotech — get its next earnings analysis in your feed
How does Rossari Biotech rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Rossari Biotech rank in Chemicals & Petrochemicals?
Compare Rossari Biotech against every Chemicals & Petrochemicals company (Q4 FY23) on revenue, margins and earnings-call signals.
Continue your research
What Rossari Biotech's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…